Back to search results

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Abroad (travel likely)RecruitingPHASE2

Conditions

Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Isabel Arrillaga-Romany, MD PhD) · iarrillaga@mgh.harvard.edu · 617-724-8770
    Contact: Principal Investigator (Isabel Arrillaga-Romany, MD PhD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Patrick Y. Wen, MD) · patrick_wen@dfci.harvard.edu · 617-632-2166
    Contact: Study coordinator (Lisa Doherty, NP) · lisa_doherty@dfci.harvard.edu · 617-632-2166
    Contact: Principal Investigator (Patrick Y Wen, MD)

  • Mayo Clinic, Rochester, Minnesota, United States

  • Columbia University Medical Center, New York, New York, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Thomas Kaley, MD) · kaleyt@mskcc.org · 212-639-5122

  • Cleveland Clinic, Cleveland, Ohio, United States

  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Jan Drappatz, MD) · drappatzj@upmc.edu · 412-864-7791

  • Lifespan / Rhode Island Hospital, Providence, Rhode Island, United States

  • UT MD Anderson Cancer Center, Houston, Texas, United States

  • Huntsman Cancer Institute, Salt Lake City, Utah, United States

  • University of Virginia Health System, Charlottesville, Virginia, United States

Study leads

  • Patrick Y Wen, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)